Methylenedianiline dihydrochloride

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:12750745	IVR	300 mg/L	300 mg/L	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Granulosa cell carcinoma	Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Changes in adrenal gland morphology	Metabolic endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Hyperplasia in thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Changes in adrenal gland morphology	Metabolic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Hyperplasia in thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Granulosa cell carcinoma	Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations
	IVR	800 mg/L	800 mg/L	Hyperplasia in pituitary gland	Neurological endocrine-mediated perturbations
	IVR	1600 mg/L	-	No significant effects observed	-
	IVR	100 mg/L	-	No significant effects observed	-
	IVR	3200 mg/L	-	No significant effects observed	-
	IVR	50 mg/L	-	No significant effects observed	-
	IVR	200 mg/L	-	No significant effects observed	-
	IVR	400 mg/L	400 mg/L	Hyperplasia in thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	400 mg/L	400 mg/L	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
PMID:3712494	IVR	300 mg/L	300 mg/L	Changes in morphology of thyroid gland	Metabolic endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Thyroid gland carcinoma	Endocrine-mediated cancer;Metabolic endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Hematopietic carcinoma	Endocrine-mediated cancer;Immunological endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Changes in liver morphology	Hepatic endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Hepatocellular carcinoma	Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations
	IVR	300 mg/L	300 mg/L	Changes in adrenal gland morphology	Metabolic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Changes in liver morphology	Hepatic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Hepatocellular carcinoma	Endocrine-mediated cancer;Hepatic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Changes in adrenal gland morphology	Metabolic endocrine-mediated perturbations
	IVR	150 mg/L	150 mg/L	Hematopietic carcinoma	Endocrine-mediated cancer;Immunological endocrine-mediated perturbations
PMID:4293143	IVR	100 mg/kg	100 mg/kg	Decrease in corticosterone levels	Neurological endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.